Antares Pharma, Inc. (ATRS)
(Delayed Data from NSDQ)
$3.04 USD
+0.06 (2.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.04 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ATRS]
Reports for Purchase
Showing records 21 - 40 ( 49 total )
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
3Q18 Results; Good Momentum; Crucial Xyosted and Partner Generic EpiPen Launches up Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Xyosted TRT Auto-Injector Approved; Launch by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Generic EpiPen Finally Approved; Xyosted PDUFA on Deck September 29; Raise Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
2Q18 Results; Solid Quarter ahead of potential Big 2H drivers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
1Q18 Results; Finally, Confirmation a Xyosted BP Study Was Done; Increased Approval Confidence; Raise Target to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Xyosted Back in the Game? Resubmission Expected 2Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
4Q17 Results; Xyosted Regulatory Update Within Weeks; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Partner Makena Approval Injects New Life; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
3Q17 Results; Base Business Revenue Upside; Still Waiting on Xyosted Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Xyosted CRL Tells Us FDA Looking for Excuse to Dodge TRT; Other Assets Unaffected; Reiterate Buy but Lower $3.50 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Xyosted Unspecified Issues Are a Head Scratcher, But Sumof- Parts Without It Still Worth Well Above After-Hours Levels
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O